PB 64 of 2025
National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025
I, Rebecca Richardson, as delegate of the Minister for Health and Ageing, make the following determination.
Dated 27 May 2025
Rebecca Richardson
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health, Disability and Ageing
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments commencing 1 June 2025
National Health (Minimum Stockholding) Determination 2023
Schedule 2—Amendments commencing 1 November 2025
National Health (Minimum Stockholding) Determination 2023
(1) This instrument is the National Health (Minimum Stockholding) Amendment Determination (No. 5) 2025.
(2) This instrument may also be cited as PB 64 of 2025.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | 1 June 2025. | 1 June 2025 |
2. Schedule 1 | 1 June 2025. | 1 June 2025 |
3. Schedule 2 | 1 November 2025. | 1 November 2025 |
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99AEKC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
1 Schedule 1 (table)
After:
Aripiprazole | Tablet 30 mg | Oral | APO‑Aripiprazole | 3 months stock by reference to usual demand |
insert:
Arsenic | Injection concentrate containing arsenic trioxide 10 mg in 10 mL | Injection | Arsenic Trioxide-AFT | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
2 Schedule 1 (table)
Omit:
Azacitidine | Powder for injection 100 mg | Injection | Azacitidine-Teva | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
3 Schedule 1 (table)
After:
Benzathine benzylpenicillin | Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe | Injection | Bicillin L-A | 6 months stock by reference to usual PBS demand |
insert:
Bisoprolol | Tablet containing bisoprolol fumarate 10 mg | Oral | NOUMED BISOPROLOL | between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand |
Bisoprolol | Tablet containing bisoprolol fumarate 2.5 mg | Oral | NOUMED BISOPROLOL | between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand |
Bisoprolol | Tablet containing bisoprolol fumarate 5 mg | Oral | NOUMED BISOPROLOL | between 1 June 2025 and 30 September 2025—0 months stock by reference to usual demand |
4 Schedule 1 (table)
Omit:
Ciclosporin | Capsule 100 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
5 Schedule 1 (table)
Omit:
Ciclosporin | Capsule 25 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
6 Schedule 1 (table)
Omit:
Ciclosporin | Capsule 50 mg | Oral | Cyclosporin Sandoz | between 1 December 2024 and 31 May 2025—0 months stock by reference to usual demand |
7 Schedule 1 (table)
After:
Dosulepin | Capsule containing dosulepin hydrochloride 25 mg | Oral | Dosulepin Viatris | 6 months stock by reference to usual demand |
insert:
Doxorubicin | Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 mL single dose vial | Injection/Intravesical | Adriamycin | between 1 June 2025 and 30 June 2025—0 months stock by reference to usual demand |
8 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | 2.5 months stock by reference to usual demand |
9 Schedule 1 (table)
After:
Felodipine | Tablet 2.5 mg (extended release) | Oral | Plendil ER | 2.5 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 1.28 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 10.20 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 12.6 mg | Transdermal | Durogesic 75 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
10 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 12.6 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 16.8 mg | Transdermal | Durogesic 100 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
11 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 2.1 mg | Transdermal | APO‑Fentanyl | 3.5 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 2.1 mg | Transdermal | Durogesic 12 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 2.55 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
12 Schedule 1 (table)
Omit:
Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | 2.5 months stock by reference to usual demand |
13 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 4.2 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 4.2 mg | Transdermal | Durogesic 25 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 5.10 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
Fentanyl | Transdermal patch 7.65 mg | Transdermal | Denpax | between 1 June 2025 and 31 August 2025—0 months stock by reference to usual demand |
14 Schedule 1 (table)
After:
Fentanyl | Transdermal patch 8.4 mg | Transdermal | APO‑Fentanyl | 3 months stock by reference to usual demand |
insert:
Fentanyl | Transdermal patch 8.4 mg | Transdermal | Durogesic 50 | between 1 June 2025 and 31 July 2025—0 months stock by reference to usual demand |
15 Schedule 1 (table)
After:
Fluconazole | Powder for oral suspension 50 mg in 5 mL, 35 mL | Oral | Diflucan | 4 months stock by reference to usual PBS demand |
insert:
Fluoxetine | Capsule 20 mg (as hydrochloride) | Oral | Fluoxetine APOTEX | between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand |
16 Schedule 1 (table)
Omit:
Furosemide | Tablet 40 mg | Oral | NOUMED FUROSEMIDE | between 1 April 2025 and 31 May 2025—0 months stock by reference to usual demand |
17 Schedule 1 (table)
Omit:
Iron polymaltose complex | Injection 100 mg (iron) in 2 mL | Injection | Ferrosig | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
18 Schedule 1 (table)
After:
Isoleucine with carbohydrate | Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50) | Oral | Isoleucine 50 | 0 months stock by reference to usual PBS demand |
insert:
Lamivudine | Tablet 150 mg | Oral | Lamivudine Viatris | after 30 September 2025—4 months stock by reference to usual demand of both Lamivudine Viatris and Lamivudine Alphapharm added together |
19 Schedule 1 (table)
Omit:
Methylprednisolone | Powder for injection 1 g (as sodium succinate) | Injection | Solu-Medrol | between 1 May 2025 and 31 May 2025—0 months stock by reference to usual demand |
20 Schedule 1 (table)
Omit:
Mycophenolic acid | Tablet containing mycophenolate mofetil 500 mg | Oral | Mycophenolate APOTEX | 4 months stock by reference to usual demand of both Mycophenolate APOTEX and ARX-MYCOPHENOLATE added together |
21 Schedule 1 (table)
After:
Ondansetron | Syrup 4 mg (as hydrochloride dihydrate) per 5 mL, 50 mL | Oral | Zofran syrup 50 mL | 4 months stock by reference to usual PBS demand |
insert:
Ondansetron | Tablet (orally disintegrating) 4 mg | Oral | Ondansetron ODT Viatris | after 30 September 2025—6 months stock by reference to usual demand of both Ondansetron ODT Viatris and Ondansetron Mylan ODT added together |
22 Schedule 1 (table)
After:
Promethazine | Injection containing promethazine hydrochloride 50 mg in 2 mL | Injection | DBL Promethazine Hydrochloride | 6 months stock by reference to usual PBS demand |
insert:
Propylene glycol | Eye drops 60 micrograms per mL, 10 mL | Application to the Eye | Systane Balance | 4 months stock by reference to usual PBS demand |
23 Schedule 1 (table)
After:
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Parbezol | 4 months stock by reference to usual demand |
insert:
Rabeprazole | Tablet containing rabeprazole sodium 10 mg (enteric coated) | Oral | Pariet | between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand |
Rabeprazole | Tablet containing rabeprazole sodium 20 mg (enteric coated) | Oral | Pariet | between 1 June 2025 and 30 November 2025—0 months stock by reference to usual demand |
24 Schedule 1 (table)
Omit:
Ramipril | Capsule 10 mg | Oral | Ramipril Winthrop | between 1 April 2025 and 31 May 2025—0 months stock by reference to usual demand |
25 Schedule 1 (table)
After:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Tenofovir ARX | 4 months stock by reference to usual demand of both Tenofovir APOTEX and Tenofovir ARX added together |
insert:
Tenofovir | Tablet containing tenofovir disoproxil fumarate 300 mg | Oral | Viread | between 1 June 2025 and 30 September 2025—2 months stock by reference to usual demand |
26 Schedule 1 (table)
After:
Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |
insert:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | CIPLA TENOFOVIR + EMTRICITABINE 300/200 | between 1 June 2025 and 30 September 2025—4 months stock by reference to usual demand |
27 Schedule 1 (table)
Omit:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | Tenofovir/Emtricitabine 300/200 APOTEX | 3 months stock by reference to usual demand of both Tenofovir/Emtricitabine 300/200 APOTEX and TENOFOVIR/EMTRICITABINE 300/200 ARX added together |
28 Schedule 1 (table)
Omit:
Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | APO-Sodium Valproate | between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Epilim EC | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Sodium Valproate Sandoz | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valprease 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valpro EC 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 200 mg | Oral | Valproate Winthrop EC 200 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | APO-Sodium Valproate | between 1 April 2025 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Epilim EC | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Sodium Valproate Sandoz | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valprease 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valpro EC 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
Valproic acid | Tablet (enteric coated) containing sodium valproate 500 mg | Oral | Valproate Winthrop EC 500 | between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand |
1 Schedule 1 (table)
After:
Tenofovir | Tablet containing tenofovir disoproxil maleate 300 mg | Oral | Tenofovir Disoproxil Viatris | after 31 January 2025— 4 months stock by reference to usual demand of both Tenofovir Disoproxil Viatris and Tenofovir Disoproxil Mylan added together |
insert:
Tenofovir with emtricitabine | Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg | Oral | TENOFOVIR/EMTRICITABINE 300/200 APX | 6 months stock by reference to usual demand |